S.BIOMEDICS develops therapies using a variety of cells, including somatic cells, immune cells, adult stem cells, and embryonic stem cells. It also manufactures and sells CFC-FECS-DF (a cosmetic ingredient). The company owns Esthefarm, a subsidiary that specializes in the manufacturing and sales of skincare products.

FECSTM technology is a 3D cell spheroid (3D spherical cell cluster) formation technology for cell function enhancement. An excellent effect is expected by enhancing cell functions and creating an environment similar to that of the body. FECSTM has a great potential for the application to the development of cell therapy products, because that is safe to the human body, and its production process is stable and is applicable to various types of cells. As a standardized and efficient neural precursor cell differentiation technology, TED technology can be applied to all pluripotent stem cell lines. By overcoming the different differentiation tendencies of each pluripotent stem cell line, it can induce efficient differentiation of all pluripotent stem cell lines into neural precursor cells. The neural precursor cells obtained as a result become the source of treatment for intractable nervous diseases.

Public

Biotech